Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants With Primary Aldosteronism

NCT07007793 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07007793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07007793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants With Primary Aldosteronism
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
August 7, 2025
Completion date
August 14, 2028
Enrollment
250 (estimated)
Sites
89

Conditions

As the registry lists them; a condition with its own page is linked.

primary hyperaldosteronism